Cargando…

Effect of epilepsy on autism symptoms in Angelman syndrome

BACKGROUND: Autism spectrum disorder and epilepsy often co-occur; however, the extent to which the association between autism symptoms and epilepsy is due to shared aetiology or to the direct effects of seizures is a topic of ongoing debate. Angelman syndrome (AS) is presented as a suitable disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakke, Kristin A., Howlin, Patricia, Retterstøl, Lars, Kanavin, Øivind J., Heiberg, Arvid, Nærland, Terje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759870/
https://www.ncbi.nlm.nih.gov/pubmed/29340132
http://dx.doi.org/10.1186/s13229-017-0185-1
_version_ 1783291286087794688
author Bakke, Kristin A.
Howlin, Patricia
Retterstøl, Lars
Kanavin, Øivind J.
Heiberg, Arvid
Nærland, Terje
author_facet Bakke, Kristin A.
Howlin, Patricia
Retterstøl, Lars
Kanavin, Øivind J.
Heiberg, Arvid
Nærland, Terje
author_sort Bakke, Kristin A.
collection PubMed
description BACKGROUND: Autism spectrum disorder and epilepsy often co-occur; however, the extent to which the association between autism symptoms and epilepsy is due to shared aetiology or to the direct effects of seizures is a topic of ongoing debate. Angelman syndrome (AS) is presented as a suitable disease model to explore this association. METHODS: Data from medical records and questionnaires were used to examine the association between age of epilepsy onset, autism symptoms, genetic aberration and communication level. Forty-eight participants had genetically verified AS (median age 14.5 years; range 1–57 years). A measure of autism symptoms (the Social Communication Questionnaire; SCQ) was completed for 38 individuals aged ≥ 4 years. Genetic cause was subgrouped into deletion and other genetic aberrations of the 15q11-q13 area. The number of signs used to communicate (< 20 sign and ≥ 20 signs) was used as a measure of nonverbal communication. RESULTS: Mean age of epilepsy onset was 3.0 years (range 3 months–7.8 years). Mean SCQ score for individuals without epilepsy was 13.6 (SD = 6.7) and with epilepsy 17.0 (SD = 5.6; p = 0.17); 58% used fewer than 20 signs to communicate. There were no age differences between groups according to presence of epilepsy, level of nonverbal communication or type of genetic aberration. SCQ scores were higher in individuals with the deletion than in those with other genetic aberrations (18.7 vs 10.8 p = 0.008) and higher in the group who used < 20 signs to communicate (19.4 vs 14.1 p = 0.007). Age of epilepsy onset was correlated with SCQ (r = − 0.61, p < 0.001). Multiple regression showed that age of seizure onset was significantly related to SCQ score (β = − 0.90; p = 0.006), even when the type of genetic abnormality was controlled (R(2) = 0.53; F = 10.7; p = 0.001). CONCLUSIONS: The study provides support for the notion that seizures themselves contribute more to autism symptoms than expected from the underlying genetic pathology alone. The study demonstrates how a rare genetic syndrome such as Angelman syndrome may be used to study the relation between epilepsy and autism symptomatology.
format Online
Article
Text
id pubmed-5759870
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57598702018-01-16 Effect of epilepsy on autism symptoms in Angelman syndrome Bakke, Kristin A. Howlin, Patricia Retterstøl, Lars Kanavin, Øivind J. Heiberg, Arvid Nærland, Terje Mol Autism Research BACKGROUND: Autism spectrum disorder and epilepsy often co-occur; however, the extent to which the association between autism symptoms and epilepsy is due to shared aetiology or to the direct effects of seizures is a topic of ongoing debate. Angelman syndrome (AS) is presented as a suitable disease model to explore this association. METHODS: Data from medical records and questionnaires were used to examine the association between age of epilepsy onset, autism symptoms, genetic aberration and communication level. Forty-eight participants had genetically verified AS (median age 14.5 years; range 1–57 years). A measure of autism symptoms (the Social Communication Questionnaire; SCQ) was completed for 38 individuals aged ≥ 4 years. Genetic cause was subgrouped into deletion and other genetic aberrations of the 15q11-q13 area. The number of signs used to communicate (< 20 sign and ≥ 20 signs) was used as a measure of nonverbal communication. RESULTS: Mean age of epilepsy onset was 3.0 years (range 3 months–7.8 years). Mean SCQ score for individuals without epilepsy was 13.6 (SD = 6.7) and with epilepsy 17.0 (SD = 5.6; p = 0.17); 58% used fewer than 20 signs to communicate. There were no age differences between groups according to presence of epilepsy, level of nonverbal communication or type of genetic aberration. SCQ scores were higher in individuals with the deletion than in those with other genetic aberrations (18.7 vs 10.8 p = 0.008) and higher in the group who used < 20 signs to communicate (19.4 vs 14.1 p = 0.007). Age of epilepsy onset was correlated with SCQ (r = − 0.61, p < 0.001). Multiple regression showed that age of seizure onset was significantly related to SCQ score (β = − 0.90; p = 0.006), even when the type of genetic abnormality was controlled (R(2) = 0.53; F = 10.7; p = 0.001). CONCLUSIONS: The study provides support for the notion that seizures themselves contribute more to autism symptoms than expected from the underlying genetic pathology alone. The study demonstrates how a rare genetic syndrome such as Angelman syndrome may be used to study the relation between epilepsy and autism symptomatology. BioMed Central 2018-01-08 /pmc/articles/PMC5759870/ /pubmed/29340132 http://dx.doi.org/10.1186/s13229-017-0185-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bakke, Kristin A.
Howlin, Patricia
Retterstøl, Lars
Kanavin, Øivind J.
Heiberg, Arvid
Nærland, Terje
Effect of epilepsy on autism symptoms in Angelman syndrome
title Effect of epilepsy on autism symptoms in Angelman syndrome
title_full Effect of epilepsy on autism symptoms in Angelman syndrome
title_fullStr Effect of epilepsy on autism symptoms in Angelman syndrome
title_full_unstemmed Effect of epilepsy on autism symptoms in Angelman syndrome
title_short Effect of epilepsy on autism symptoms in Angelman syndrome
title_sort effect of epilepsy on autism symptoms in angelman syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759870/
https://www.ncbi.nlm.nih.gov/pubmed/29340132
http://dx.doi.org/10.1186/s13229-017-0185-1
work_keys_str_mv AT bakkekristina effectofepilepsyonautismsymptomsinangelmansyndrome
AT howlinpatricia effectofepilepsyonautismsymptomsinangelmansyndrome
AT retterstøllars effectofepilepsyonautismsymptomsinangelmansyndrome
AT kanavinøivindj effectofepilepsyonautismsymptomsinangelmansyndrome
AT heibergarvid effectofepilepsyonautismsymptomsinangelmansyndrome
AT nærlandterje effectofepilepsyonautismsymptomsinangelmansyndrome